Response to comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’

Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Mast, Alan E, Wolberg, Alisa S, Gailani, David, Garvin, Michael R, Alvarez, Christiane, Miller, J Izaak, Jones, Piet, Aronow, Bruce, Jacobson, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Computational and Systems Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752086/
https://www.ncbi.nlm.nih.gov/pubmed/35014952
http://dx.doi.org/10.7554/eLife.74951
Descripción
Sumario:Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.

Ejemplares similares